3SBIO (01530) announced that on December 2, 2025 (before trading hours), the company entered into a placement agreement with a sole placing agent. Under the agreement, the company conditionally agreed to place a total of 105 million shares at HK$29.62 per share to no fewer than six placees through the sole placing agent.

The placement price of HK$29.62 per share was determined on a fair basis by the company and the sole placing agent, referencing the prevailing market price of the shares. This represents a 6.50% discount to the closing price of HK$31.68 per share on the Hong Kong Stock Exchange on the last trading day prior to the placement agreement date.

Assuming no changes in the company's issued share capital from the announcement date to completion, the 105 million placement shares will account for approximately 4.14% of the total issued share capital post-enlargement.

The estimated gross proceeds and net proceeds (after deducting placement commissions, related expenses, and professional fees) from the placement are approximately HK$3.115 billion and HK$3.087 billion, respectively.

The company intends to allocate the net proceeds as follows: approximately 80% will be used for R&D-related expenses, including (a) advancing clinical studies of innovative drugs in the pipeline in China and the U.S., such as 705 (PD1/HER2), 706 (PD1/PDL1), 008 (B7H3/IL15), 59 (MUC17/CD3/CD28), 626 (BDCA2), and 627 (TL1A); (b) supporting label expansion or overseas clinical trials for commercialized drugs like TPIAO (TPO) and EPIAO (EPO) to enhance product value and market coverage; and (c) building global infrastructure and supporting facilities. The remaining 20% will be allocated for working capital and general corporate purposes to support the group's ongoing operations and strategic plans.